Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora

European Journal of Dermatology

Volumn 19, Issue 5, 2009, Pages 451-455

  Zhang, Jun Min ^a   Xi, Li Yan ^a   Zhang, Hui ^a   Xie, Zhi ^a   Sun, Jiu Feng ^a   Li, Xi Qing ^a   Lu, Sha ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chromoblastomycosis; Fonsecaea monophora; Itraconazole; Synergistic effects; Terbinafine

Indexed keywords

ITRACONAZOLE; TERBINAFINE;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA PARAPSILOSIS; CELL ISOLATION; CHROMOMYCOSIS; CLINICAL ARTICLE; DRUG POTENTIATION; FEMALE; FONSECAEA; FONSECAEA MONOPHORA; FUNGAL STRAIN; HUMAN; IN VITRO STUDY; INOCULATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTIFUNGAL AGENTS; ASCOMYCOTA; DRUG SYNERGISM; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES;

EID: 69849096310     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2009.0728     Document Type: Article

References (26)

1. Lopez Martinez R, Mendez Tovar LJ. Chromoblastomycosis. Clin Dermatol 2007; 25: 188-194
2. De Hoog GS, Attili-angelis D, Vicente VA, et al. Molecular ecology and pathogenic potential of Fonsecaea species. Med Mycol 2004; 42: 405-416 (Pubitemid 39445472)
3. Esterre P, Pecarrere JL, Raharisolo C, et al. Squamous cell carcinoma arising from chromomycosis. Report of two cases. Ann Pathol 1999; 19: 516-520
4. Brand ME, Warnock DW. Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J Chemother 2003; 15 (Suppl. 2): 36-47. (Pubitemid 38021614)
5. Park SG, Oh SH, Suh SB, et al. A case of chromoblastomycosis with an unusual clinical manifestation caused by Phialophora verrucosa on an unexposed area: treatment with a combination of amphotericin B and 5-flucytosine. Br J Dermatol 2005; 152: 560-564
6. Minotto R, Bernardi CD, Mallmann LF, et al. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. J Am Acad Dermatol 2001; 44: 585-592 (Pubitemid 32249512)
7. Zhang J, Xi L, Lu C, et al. Successful treatment for chromoblastomycosis caused by Fonsecaea monophora: a report of three cases in Guangdong, China. Mycoses 2009; 52: 176-181
8. Kumarasinghe SP, Kumarasinghe MP. Itraconazole pulse therapy in chromoblastomycosis. Eur J Dermatol 2000; 10: 220-222
9. Xibao Z, Changxing L, Quan L, et al. Treatment of chromoblastomycosis with terbinafine: a report of four cases. J Dermatol Treat 2005; 16: 121-124 (Pubitemid 40676913)
10. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. NCCLS document M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
11. Pfaller MA, Rinaldi MG, Galgiani JN, et al. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother 1990; 34: 1648-1654
12. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47: 331-385
13. Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: Lorain V, ed. Antibiotics in laboratory medicine, 4th ed. Baltimore, Md.: The Williams & Wilkins Co., 1989: 330-396
14. Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol 2007; 45: 569-587 (Pubitemid 350176707)
15. Dannaoui E, Lortholary O, Dromer F. Methods for antifungal combination studies in vitro and in vivo in animal models. J Mycol Med 2003; 13: 73-85. (Pubitemid 36806846)
16. Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol 2002; 40: 529-534
17. Meletiadis J, Mouton JW, Rodriguez-Tudela JL, et al. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolifcans. Antimicrob Agents Chemother 2000; 44: 470-472
18. Kovarik JM, Mueller EA, Zehender IT, et al. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Agents Chemother 1995; 39: 2738-2741
19. Patterson TF, Peters J, Levine SM, et al. Systemic availability of itraconazole in lung transplantation. Antimicrob Agents Chemother 1996; 40: 2210-2217 (Pubitemid 26296278)
20. Andrade TS, Castro LG, Nunes RS, et al. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses 2004; 47: 216-221
21. Horsburgh Jr. CR, Feldman S, Ridzon R, et al. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis 2000; 31: 633-639
22. Polak A. The past, present and future of antimycotic combination therapy. Mycoses 1999; 42: 355-370 (Pubitemid 29457850)
23. Sobel JD. Combination Therapy for Invasive Mycoses: Evaluation of Past Clinical Trial Designs. Clin Infect Dis 2004; 39: S224-7.
24. Poirriez J, Breuillard F, Francois N, et al. A case of chromomycosis treated by a combination of cryotherapy, shaving, oral 5- fluorocytosine, and oral amphotericin B. Am J Trop Med Hyg 2000; 63: 61-63 (Pubitemid 32423096)
25. Nagao K, Matsumoto H, Sugiura M, et al. A case of chromomycosis arising in a Japanese-Brazilian patient. Jpn J Mycol 2001; 42: 119-122
26. Takemoto K, Yamamoto Y, Ueda Y. Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans. Microbiol Immunol 2006; 50: 579-86b. (Pubitemid 44285284)